Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy

Immunotherapy

Volumn 9, Issue 2, 2017, Pages 115-121

  Moreira, Alvaro ^a   Leisgang, Waltraud ^a   Schuler, Gerold ^a   Heinzerling, Lucie ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

biomarker; blood eosinophilia; eosinophils; immunotherapy; melanoma; prognosis

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; ANIMAL; CELL COUNT; EOSINOPHIL; IMMUNOTHERAPY; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOMARKERS, TUMOR; CELL COUNT; EOSINOPHILS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 85011103419     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2016-0138     Document Type: Article

References (33)

1. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J. Immunol. 178(7), 4222-4229 (2007).
2. Costain DJ, Guha AK, Liwski RS, Lee TD. Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism. Cancer Immunol. Immunother. 50(6), 293-299 (2001).
3. Ikutani M, Yanagibashi T, Ogasawara M, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J. Immunol. 188(2), 703-713 (2012).
4. Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF-Alpha and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J. Immunol. 185(12), 7443-7451 (2010).
5. Lowe D, Jorizzo J, Hutt MS. Tumour-Associated eosinophilia: a review. J. Clin. Pathol. 34(12), 1343-1348 (1981).
6. Samoszuk M. Eosinophils and human cancer. Histol. Histopathol. 12(3), 807-812 (1997).
7. Ohashi Y, Ishibashi S, Suzuki T, et al. Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma. Anticancer Res. 20(5A), 3025-3030 (2000).
8. Samoszuk M, Deng T, Hamamura MJ, Su MY, Asbrock N, Nalcioglu O. Increased blood clotting, microvascular density, and inflammation in eotaxin-secreting tumors implanted into mice. Am. J. Pathol. 165(2), 449-456 (2004).
9. Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-Associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J. Immunother. 30(1), 16-28 (2007).
10. Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol. Res. 2(1), 1-8 (2014).
11. Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M. Involvement of eosinophils in the anti-Tumor response. Cancer Immunol. Immunother. 61(9), 1527-1534 (2012).
12. Prizment AE, Vierkant RA, Smyrk TC, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa Womens Health Study. Mod. Pathol. 29(5), 516-527 (2016).
13. Sakkal S, Miller S, Apostolopoulos V, Nurgali K. Eosinophils in cancer: favourable or unfavourable?. Curr. Med. Chem. 23(7), 650-666 (2016).
14. Minton K. Granulocytes: eosinophils enable the antitumour T cell response. Nat. Rev. Immunol. 15(6), 333 (2015).
15. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat. Immunol. 16(6), 609-617 (2015).
16. Cormier SA, Taranova AG, Bedient C, et al. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J. Leukoc. Biol. 79(6), 1131-1139 (2006).
17. Capobianco A, Manfredi AA, Monno A, Rovere-Querini P, Rugarli C. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J. Immunother. 31(5), 458-465 (2008).
18. Lipson EJ, Sharfman WH, Chen S, et al. Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med. 13, 214 (2015).
19. Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann. Oncol. 24(6), 1697-1703 (2013).
20. Umansky V, Utikal J, Gebhardt C. Predictive immune markers in advanced melanoma patients treated with ipilimumab. Oncoimmunology 5(6), e1158901 (2016).
21. Weide B, Martens A, Hassel JC, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin. Cancer Res. doi:10.1158/1078-0432.ccr-16-0127 (2016) (Epub ahead of print).
22. Groß S, Erdmann M, Schuler G. Dendritic cell vaccination on the long run: 11-year survival in advanced melanoma patients is equivalent to ipilimumab-Treatment. (2016) (Submitted).
23. Rodgers S, Rees RC, Hancock BW. Changes in the phenotypic characteristics of eosinophils from patients receiving recombinant human interleukin-2 (rhIL-2) therapy. Br. J. Haematol. 86(4), 746-753 (1994).
24. Schaefer JT, Patterson JW, Deacon DH, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J. Transl. Med. 8, 79 (2010).
25. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin. Cancer Res. 15(22), 7029-7035 (2009).
26. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24(31), 5060-5069 (2006).
27. Sedgwick JB, Frick WE, Sondel PM, Hank JA, Borden E, Busse WW. The appearance of hypodense eosinophils during interleukin-2 treatment. J. Allergy Clin. Immunol. 85(3), 557-566 (1990).
28. Rivoltini L, Viggiano V, Spinazze S, et al. In vitro anti-Tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int. J. Cancer 54(1), 8-15 (1993).
29. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-Associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).
30. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
31. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-Agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
32. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013).
33. Gebhardt C, Sevko A, Jiang H, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin. Cancer Res. 21(24), 5453-5459 (2015).